Milnacipran plasma levels and antidepressant response in Japanese major depressive patients
Milnacipran plasma levels and antidepressant response in Japanese major depressive patients
复制标题
日本重度抑郁症患者米那普仑血浆水平和抗抑郁反应
DOI：
--
复制
发表时间：
2003
期刊：
影响因子：
--
通讯作者：
Y. Hishikawa
中科院分区：
文献类型：
--
作者：
H. Higuchi;Keizo Yoshida;Hitoshi Takahashi;Shingo Naito;M. Kamata;Kenich Ito;Kazuhiro Sato;K. Tsukamoto;T. Shimizu;M. Nakanishi;Y. Hishikawa
对49例无精神病性症状的抑郁症患者进行了为期6周的米那普仑治疗，观察其抗抑郁作用与血浆浓度的关系。第一周米那普仑的日剂量为50 mg/天，此后高达100 mg/天。于治疗前及治疗后1、2、4、6周采用蒙哥马利和艾斯伯格抑郁量表（MADRS）评定抑郁症状。34例患者（69.4%）为应答者（定义为基线MADRS评分降低50%或以上）。从本研究开始后1周开始，观察到应答者和非应答者之间MADRS评分的显著差异（p = 0.004，非配对t检验）。应答者的平均血浆米那普仑水平（82.0 ± 29.4 ng/ml）与非应答者的平均血浆米那普仑水平（78.6 ± 23.1 ng/ml）相似;应答者和非应答者之间无显著差异。在最终MADRS评分和米那普仑血浆水平之间未获得显著的线性或曲线关系。虽然米那普仑的血浆水平和抗抑郁反应之间没有显著关系，但米那普仑应被视为治疗重度抑郁症患者的有效药物。版权所有© 2003年约翰威利父子有限公司。
The relationship between antidepressant effects and plasma levels of milnacipran was studied in 49 cases of major depression without psychotic features during 6 weeks of milnacipran treatment. The daily dose of milnacipran was 50 mg/day for the first week, and up to 100 mg/day thereafter. Depressive symptoms were evaluated by the Montgomery and Åsberg depression rating scale (MADRS) before treatment and at 1, 2, 4 and 6 weeks after the beginning of this study. Thirty‐four patients (69.4%) were responders (defined as a 50% or greater decrease in the baseline MADRS score). Significant differences of MADRS scores were seen from 1 week after the beginning of this study (p = 0.004, unpaired t‐test) between responders and nonresponders. The mean plasma milnacipran level of responders, 82.0 ± 29.4 ng/ml, was similar to that of non‐responders, 78.6 ± 23.1 ng/ml; there was no significant difference between responders and nonresponders. Neither a significant linear nor a curvilinear relationship was obtained between the final MADRS score and the plasma levels of milnacipran. Although there was no significant relationship between the plasma levels of milnacipran and the antidepressant response, milnacipran should be considered an efficacious agent in the treatment of major depressive patients. Copyright © 2003 John Wiley & Sons, Ltd.